β2microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients

e15071 Background: Oxaliplatin has been widely used for the treatment of colorectal cancer. The mechanism of action of platinum compounds such as oxaliplatin is to bind to a DNA molecule in the form of a platinum-DNA-adduct. Excision repair cross complementation group 1 (ERCC1), which plays a major role in the nucleotide excision pathway, has a polymorphism in codon 118, and is reported to be associated with a resistance to platinum-based therapy. Thymidylate synthase (TS) and dehydropyrimidine dehydrogenase (DPD) are key enzymes of 5-FU metabolism and are well known to be associated with a response to 5-FU-based therapy. Methods: Twenty-one colorectal cancer patients (male:female = 7:14; median age, 65) treated with a combination of oxaliplatin and S-1 as a first-line therapy were analyzed for ERCC1 codon 118 polymorphism and the mRNA expression levels of TS, ERCC1, and DPD. Formalin-fixed paraffin- embedded surgical specimens were used and t-RNA and DNA were extracted. The mRNA expression levels were measured using real-time RT-PCR, and the polymorphism was analyzed using the allelic discrimination method together with real-time PCR. Results: No correlation was observed between ERCC1 codon118 polymorphism and any response to the chemotherapy. ERCC1 mRNA levels tended to be higher in the patients with wild-type homozygous alleles in codon 118 than in those with at least one mutant allele(1.19 vs.0.68: p= 0.15). Patients with both high TS and ERCC1 mRNA levels showed a significantly lower response rate than the others (25% vs. 67%, p=0.02). No relationship was seen between DPD mRNA expression levels and the response. Conclusions: The mRNA expression levels of TS and ERCC1 appear to be useful markers for the treatment of S-1 and oxaliplatin. No particular usefulness of ERCC1 codon 118 polymorphism was verified. No significant financial relationships to disclose.

Download Full-text

An Optimal mRNA Marker for OSNA (One-step Nucleic Acid Amplification) Based Lymph Node Metastasis Detection in Colorectal Cancer Patients

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hys227 ◽

2013 ◽

Vol 43 (3) ◽

pp. 264-270 ◽

Cited By ~ 13

Author(s):

N. Yamamoto ◽

M. Daito ◽

K. Hiyama ◽

J. Ding ◽

K. Nakabayashi ◽

...

Keyword(s):

Colorectal Cancer ◽

Lymph Node ◽

Nucleic Acid ◽

Lymph Node Metastasis ◽

Cancer Patients ◽

Nucleic Acid Amplification ◽

Node Metastasis ◽

One Step ◽

Colorectal Cancer Patients

Download Full-text

Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients

International Journal of Cancer ◽

10.1002/ijc.27341 ◽

2011 ◽

Vol 131 (6) ◽

pp. 1307-1317 ◽

Cited By ~ 9

Author(s):

Tomonori Akagi ◽

Naoki Hijiya ◽

Masafumi Inomata ◽

Norio Shiraishi ◽

Masatsugu Moriyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cancer Patients ◽

Poor Prognosis ◽

Node Metastasis ◽

Colorectal Cancer Patients

Download Full-text

Circulating Galectin-1 and 90K/Mac-2BP Correlated with the Tumor Stages of Patients with Colorectal Cancer

BioMed Research International ◽

10.1155/2015/306964 ◽

2015 ◽

Vol 2015 ◽

pp. 1-7 ◽

Cited By ~ 7

Author(s):

Keng-Liang Wu ◽

Hong-Hwa Chen ◽

Chen-Tzi Pen ◽

Wen-Ling Yeh ◽

Eng-Yen Huang ◽

...

Keyword(s):

Colorectal Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Carcinoembryonic Antigen ◽

Cancer Patients ◽

Enzyme Linked Immunosorbent Assay ◽

Node Metastasis ◽

Tumor Stages ◽

Galectin 3 ◽

Colorectal Cancer Patients

Background. The simultaneous correlation of serum galectin-1, galectin-3, and 90K/Mac-2BP levels with clinical stages of patients with colorectal cancer has not yet been clarified. We plan to measure the serum levels of galectin-1, galectin-3, and 90K/Mac-2BP of patients at different stages of colorectal cancer and analyze the correlation of these galectins with stages of colorectal cancers.Methods. 198 colorectal cancer patients (62 ± 13 (range 31–85) years old, 43.6% female) were recruited for this study. Subjects’ blood samples were checked for serum galectin-1, galectin-3, 90K/Mac-2BP, and carcinoembryonic antigen by sandwich enzyme-linked immunosorbent assay. We determined the correlation between plasma concentrations with clinical tumor stages.Results. Colorectal cancer patients with larger cancer sizes (stages T3, T4 rather than T1, T2) have higher serum 90K/Mac-2BP (P= 0.014) and patients with lymph node metastasis have higher serum galectin-1 (P= 0.002) but there was not a significant correlation between galectin-3 and tumor staging of colon cancer. In colorectal cancer patients even with normal carcinoembryonic antigen, serum galectin-1 could predict more lymph node metastasis.Conclusions. We found 90K/Mac-2BP correlated with the size of colorectal cancer. Galectin-1 but not galectin-3 was associated with lymph node metastasis. Galectin-1 could predict more lymph node metastasis in colorectal cancer patients with normal serum carcinoembryonic antigen.

Download Full-text